<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894619</url>
  </required_header>
  <id_info>
    <org_study_id>ILDYS-ISRNI-2015003</org_study_id>
    <secondary_id>RC20160501608</secondary_id>
    <nct_id>NCT02894619</nct_id>
  </id_info>
  <brief_title>Urinary and Anorectal Functional Disorders and Their Impact on CF Adults (PerineoMucoRMO)</brief_title>
  <acronym>PerineoMuco</acronym>
  <official_title>Assessment of the Prevalence and Severity of Urinary and Ano-rectal Functional Disorders and Their Impact on Quality of Life and Sexuality on CF Adults of the North-West CF Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ildys</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vaincre la Mucoviscidose</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondation Ildys</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study evaluates prevalence of functional perinea disorders (stress urinary&#xD;
      incontinence, overactive bladder syndrome, dysuria, anal incontinence) on CF adults patients&#xD;
      of the North-West CF Network. Its aims are to measure the severity of urinary and anorectal&#xD;
      symptoms ; assess their impact on patients' quality of life, sexuality, care and social life&#xD;
      and relationships ; identify the medical and demographic factors associated with the severity&#xD;
      of urinary and anorectal disorders and their impact and determine the relationship between&#xD;
      the severity of these disorders, various repercussions, and risk factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urine and/or anal leakage are more frequent and troublesome for CF patients: leaks occur&#xD;
      during efforts or laugh like in other people, but also when coughing or sneezing, which are&#xD;
      amplified during periods of exacerbation and with the degradation of the pulmonary condition.&#xD;
      In addition, fear of leakage can disrupt medical care: discomfort during physiotherapy,&#xD;
      pulmonary function test. Urinary and anorectal functional disorders are therefore not only a&#xD;
      factor degrading the quality of life but also a risk factor for worsening bronchial&#xD;
      obstruction, patients limiting their cough and / or their care to avoid episodes of leakage.&#xD;
      Given the lack literature data, investigators wanted to explore these areas.&#xD;
&#xD;
      Validated and specific questionnaires will be self and anonymously administered to adult&#xD;
      patients (n=175). The time requested to fill the forms is estimated to 1H. Questionnaires&#xD;
      about sexual health are optional.&#xD;
&#xD;
      Prospects considered, depending on the results, are:&#xD;
&#xD;
        -  Extension to the adolescent population (14 and over);&#xD;
&#xD;
        -  National extension;&#xD;
&#xD;
        -  Systematic proposal of a screening and an appropriate management of pelvic floor&#xD;
           functional disorders, depending on influent characteristics (age, gender ...):&#xD;
           multidisciplinary working group to develop guidelines and specific tools for&#xD;
           professional training and / or patient education;&#xD;
&#xD;
        -  Implementation of a comparative study of interventions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Symptom Profile (USP) score</measure>
    <time_frame>at time of inclusion</time_frame>
    <description>Assesses lower urinary tract symptoms (stress urinary incontinence, overactive bladder syndrome and dysuria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wexner Fecal Incontinence Scale</measure>
    <time_frame>at time of inclusion</time_frame>
    <description>Assesses anal incontinence and its impact on quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-Qualiveen questionnaire</measure>
    <time_frame>at time of inclusion</time_frame>
    <description>Assesses impact of urinary disorders on quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystic Fibrosis Questionnaire-Revised (CFQ-R)</measure>
    <time_frame>at time of inclusion</time_frame>
    <description>Assesses quality of live related to cystic fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF5) questionnaire</measure>
    <time_frame>at time of inclusion</time_frame>
    <description>Assesses male sexual dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index (FSFI)</measure>
    <time_frame>at time of inclusion</time_frame>
    <description>Assesses female sexual dysfunction</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Informations Questionnaire</measure>
    <time_frame>at time of inclusion</time_frame>
    <description>identification and prevalence of risk factors; impact degree of disorders on care, social and love life, sexuality</description>
  </other_outcome>
  <enrollment type="Actual">180</enrollment>
  <condition>Cystic Fibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        CF adults patients of the French North-West CF Network&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women 18 years and over&#xD;
&#xD;
          -  Cystic fibrosis confirmed by sweat test or genetic&#xD;
&#xD;
          -  Followed in an adult or mixed CF Center of the French North-West CF Network&#xD;
&#xD;
          -  Not transplanted and not entered on the waiting list for transplantation&#xD;
&#xD;
          -  In a stable condition for at least 4 weeks&#xD;
&#xD;
          -  Able to understand and respect the protocol and its requirements&#xD;
&#xD;
          -  Who signed the consent prior to any other procedure protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major patients under guardianship / curatorship&#xD;
&#xD;
          -  Patients seen in emergency situation&#xD;
&#xD;
          -  Pregnant patients&#xD;
&#xD;
          -  Dialysis patients&#xD;
&#xD;
          -  Patients with urolithiasis&#xD;
&#xD;
          -  Patients with severe exacerbation at the time of inclusion&#xD;
&#xD;
          -  Patients on intravenous antibiotics within 4 weeks prior to inclusion&#xD;
&#xD;
          -  Patient with an urinary tract infection (evaluation by dipstick at the time of&#xD;
             inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie Ramel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fondation Ildys</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katelyne Hubeaux, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fondation Ildys</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CF Center - University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF Center - Hôpital Laennec</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF Center - Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF Center - Fondation Ildys Site de Perharidy</name>
      <address>
        <city>Roscoff</city>
        <zip>29684</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF Center - Groupe Hospitalier Sud Réunion</name>
      <address>
        <city>St Pierre</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF Center - CH Bretagne Atlantique</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.reseau-muco-ouest.fr/projets/22-perineomuco</url>
    <description>Informations aboit project</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urinary incontinence</keyword>
  <keyword>anal incontinence</keyword>
  <keyword>sexuality</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

